

CORRECTION

Open Access



Correction: In vitro drug testing using patient-derived ovarian cancer organoids

Lin-Yu Chen^{1†}, Yu-Ting Chou^{1†}, Phui-Ly Liew^{2,3}, Ling-Hui Chu¹, Kuo-Chang Wen^{1,4}, Shiou-Fu Lin², Yu-Chun Weng⁵, Hui-Chen Wang^{4,6}, Po-Hsuan Su⁷ and Hung-Cheng Lai^{1,4,5,6*}

Correction: *J Ovarian Res* 17, 194 (2024)

<https://doi.org/10.1186/s13048-024-01520-2>

Following publication of the original article [1], the authors identified an error in Table 1 caption and content.

[†]Lin-Yu Chen and Yu-Ting Chou contributed equally to this work.

The online version of the original article can be found at <https://doi.org/10.1186/s13048-024-01520-2>.

*Correspondence:

Hung-Cheng Lai

hclai30656@gmail.com; hclai@tmu.edu.tw

¹Department of Obstetrics and Gynecology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan

²Department of Pathology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan

³Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

⁴Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

⁵Translational Epigenetics Center, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan

⁶Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan

⁷College of Health Technology, National Taipei University of Nursing and Health Sciences, Taipei 11219, Taiwan



Incorrect table.**Table 1** The characteristics of patients with ovarian cancer (V5)

Adjuvant chemotherapy	Survival status	BRCA gene status	Organoid culture	Organoid expansion
Paclitaxel and carboplatin × 6 cycles, followed by lipodox × 12 cycles, then second debulking then paclitaxel and carboplatin × 6 cycles	Alive	Wild type	Success	No
Paclitaxel and carboplatin × 9 cycles	Alive	Unexamined	Failed	-
Paclitaxel and carboplatin × 6 cycles, followed by lipodox × 3 cycles, then gemcitabine and carboplatin × 3 cycles	Expired	Unexamined	Success	Yes
Not received due to acute stroke	Expired	Unexamined	Success	Yes
Paclitaxel and carboplatin × 4 cycles, followed by interval debulking, then paclitaxel and carboplatin × 6 cycles, then lipodox, carboplatin and bevacizumab × 6 cycles	Alive	Wild type	Success	Yes
Paclitaxel and carboplatin × 4 cycles, followed by interval debulking, then paclitaxel and carboplatin × 6 cycles, then lipodox, carboplatin and bevacizumab × 6 cycles	Alive	Wild type	Failed	-
Paclitaxel and carboplatin × 6 cycles, then lipodox × 6 cycles	Alive	Mutation	Success	Yes
Paclitaxel and cisplatin × 4 cycles, then lipodox and bevacizumab × 5 cycles, then gemcitabine and bevacizumab × 2 cycles, then topotecan × 8 cycles	Expired	Unexamined	Failed	-
Paclitaxel, carboplatin and bevacizumab × 9 cycles, followed by second debulking, then bevacizumab, paclitaxel and carboplatin × 6 cycles, then lipodox × 3 cycles, then gemcitabine × 2 cycles	Expired	Wild type	Success	Yes
Paclitaxel and carboplatin × 4 cycles	Alive	Unexamined	Success	Yes
Gemcitabine and carboplatin × 1 cycle	Expired	Unexamined	Success	Yes
Rejected	Expired	Unexamined	Success	Yes
Not received	Alive	Unexamined	Success	Yes
Paclitaxel and carboplatin × 2 cycles, followed by lipodox × 3 cycles, then gemcitabine × 3 cycle	Expired	Wild type	Success	Yes
Paclitaxel and cisplatin × 6 cycles, then lipodox × 3 cycles, then gemcitabine and cisplatin × 2 cycles, followed by secondary optimal debulking, then gemcitabine and cisplatin × 2 cycles	Alive	Not received	Success	Yes
Paclitaxel and carboplatin × 6 cycles, then lipodox and carboplatin × 4 cycles	Alive	Unexamined	Success	No
Not received	Alive	Unexamined	Success	Yes
Paclitaxel and carboplatin × 2 cycles, followed by lipodox × 3 cycles, then gemcitabine × 3 cycles	Expired	Wild type	Success	Yes
Paclitaxel and carboplatin × 1 cycle, then second debulking surgery, followed by lipodox and bevacizumab × 1 cycle, then gemcitabine, carboplatin and bevacizumab × 8 cycles	Alive	Unexamined	Success	Yes
Paclitaxel and cisplatin × 1 cycle, then gemcitabine and paclitaxel × 3 cycles	Expired	Unexamined	Failed	-
Paclitaxel and cisplatin × 6 cycles	Alive	Unexamined	Success	Yes

Correct table.**Table 1** The characteristics of patients with ovarian cancer

Original ID	Sample ID	Cancer type	Age	FIGO stage	Neoadjuvant chemotherapy	Debulking status	Adjuvant chemotherapy	Survival status	BRCA gene status	Organoid culture	Organoid expansion
OvCa-19	HGSC-1	High grade serous	54	IIIC	Not received	Suboptimal	Paclitaxel and carboplatin x 6 cycles, followed by lipodox x12 cycles, then second debulking then paclitaxel and carboplatin x6 cycles	Alive	Wild type	Success	No
OvCa-21	EM-1	Endometrioid	40	IC1	Not received	Optimal	Paclitaxel and carboplatin x 9 cycles	Alive	Unexamined	Failed	-
OvCa-26	MC-1	Mucinous	37	IVB	Not received	Optimal	Paclitaxel and carboplatin x 6 cycles, followed by lipodox x 3 cycles, then gemcitabine and carboplatin x3 cycles	Expired	Unexamined	Success	Yes
OvCa-28	MC-2	Mucinous	66	IIIA	Not received	Optimal	Not received due to acute stroke	Expired	Unexamined	Success	Yes
OvCa-29	HGSC-2	High grade serous	61	IVB	Not received	Suboptimal	Paclitaxel and carboplatin x 4 cycles, followed by interval debulking, then paclitaxel and carboplatin x 6 cycles, then lipodox, carboplatin and bevacizumab x6 cycles	Alive	Wild type	Success	Yes
OvCa-32	HGSC-3	High grade serous	62	IVB	Not received	Suboptimal	Paclitaxel and carboplatin x 4 cycles, followed by interval debulking, then paclitaxel and carboplatin x 6 cycles, then lipodox, carboplatin and bevacizumab x6 cycles	Alive	Wild type	Failed	-
OvCa-33	HGSC-4	High grade serous	41	IIIC	Not received	Suboptimal	Paclitaxel and carboplatin x 6 cycles, then lipodox x 6 cycles	Alive	Mutation	Success	Yes

Table 1 (continued)

Original ID	Sample ID	Cancer type	Age	FIGO stage	Neoadjuvant chemotherapy	Debulking status	Adjuvant chemotherapy	Survival status	BRCA gene status	Organoid culture	Organoid expansion
OvCa-34	MC-3	Mucinous	43	IC1	Not received	Optimal	Paclitaxel and cisplatin x4 cycles, then lipodox and bevacizumab x 5 cycles, then gemcitabine and bevacizumab x 2 cycles, then topotecan x 8 cycles	Expired	Unexamined	Failed	-
OvCa-37	CCSC-1	Carcinoma	61	IIIC	Not received	Optimal	Paclitaxel, carboplatin and bevacizumab x 9 cycles, followed by second debulking, then bevacizumab, paclitaxel and carboplatin x 6 cycles, then lipodox x 3 cycles, then gemcitabine x2 cycles	Expired	Wild type	Success	Yes
OvCa-38	CCC-1	Clear cell	32	IC1	Not received	Optimal	Paclitaxel and carboplatin x 4 cycles	Alive	Unexamined	Success	Yes
OvCa-40	CCC-2	Clear cell	49	IIIC	Bevacizumab, paclitaxel and cisplatin x 3 cycle then paclitaxel and carboplatin x 2 cycle	Suboptimal	Gemcitabine and carboplatin x1 cycle	Expired	Unexamined	Success	Yes
OvCa-41	CCC-3	Clear cell	50	IIIB	Not received	Optimal	Rejected	Expired	Unexamined	Success	Yes
OvCa-42	MC-4	Mucinous	47	IC1	Not received	Optimal	Not received	Alive	Unexamined	Success	Yes
OvCa-43	HGSC-5	High grade serous	55	IIIC	Paclitaxel and carboplatin x 4 cycle	Optimal	Paclitaxel and carboplatin x 2 cycles, followed by lipodox x 3 cycles, then gemcitabine x3 cycle	Expired	Wild type	Success	Yes

Table 1 (continued)

Original ID	Sample ID	Cancer type	Age	FIGO stage	Neoadjuvant chemotherapy	Debulking status	Adjuvant chemotherapy	Survival status	BRCA gene status	Organoid culture	Organoid expansion
OvCa-44	EM-2	Endometrioid	58	IIB	Not received	Suboptimal	Paclitaxel and cisplatin x 6 cycles, then lipodox x 3 cycles, then gemcitabine and cisplatin x2 cycles, followed by secondary optimal debulking, then gemcitabine and cisplatin x2 cycles	Alive	Unexamined	Success	Yes
OvCa-45	HGSC-6	High grade serous	70	IIIC	Not received	Optimal	Paclitaxel and carboplatin x 6 cycles, then lipodox and carboplatin x4 cycles	Alive	Unexamined	Success	No
OvCa-46	MC-5	Mucinous	44	IC1	Not received	Optimal	Not received	Alive	Unexamined	Success	Yes
OvCa-49	HGSC-7	High grade serous	55	IIIC	Paclitaxel and cisplatin x 4 cycle	Optimal	Paclitaxel and carboplatin x 2 cycles, followed by lipodox x 3 cycles, then gemcitabine x3 cycles	Expired	Wild type	Success	Yes
OvCa-50	CCC-4	Clear cell	45	IIIC	Not received	Optimal	Paclitaxel and carboplatin x 1 cycle, then second debulking surgery, followed by lipodox and bevacizumab x 1 cycle, then gemcitabine, carboplatin and bevacizumab x 8 cycles.	Alive	Unexamined	Success	Yes
OvCa-51	CCSC-2	Carcinosarcoma	51	IIIA2	Not received	Optimal	Paclitaxel and cisplatin x 1 cycle, then gemcitabine and paclitaxel x 3 cycles	Expired	Unexamined	Failed	-
OvCa-54	CCC-6	Clear cell	51	IIB	Not received	Optimal	Paclitaxel and cisplatin x 6 cycles	Alive	Unexamined	Success	Yes

The original article [1] has been corrected.

Published online: 05 December 2024

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Chen LY, Chou YT, Liew PL, et al. In vitro drug testing using patient-derived ovarian cancer organoids. *J Ovarian Res.* 2024;17:194. <https://doi.org/10.1186/s13048-024-01520-2>.